Literature DB >> 29213446

Psychosis and concurrent impulse control disorder in Parkinson's disease: A review based on a case report.

Bruno Fukelmann Guedes1, Marcia Rubia Gonçalves1, Rubens Gisbert Cury2.   

Abstract

Psychosis, impulse control disorders (e.g., pathological gambling and hypersexuality) and repetitive behaviors such as punding are known psychiatric complications of Parkinson's disease (PD). Impulsive, compulsive and repetitive behaviors are strongly associated with dopamine-replacement therapy. We present the case of a 58-year-old man with PD and a myriad of psychiatric symptoms. Concurrent psychosis, punding and pathological gambling developed more than six years after the introduction of pramipexole and ceased shortly after the addition of quetiapine and discontinuation of pramipexole. This report emphasizes the importance of monitoring for a wide array of psychiatric symptoms in patients on dopamine replacement therapy.

Entities:  

Keywords:  Parkinson's disease; gambling; impulse control disorders; psychotic disorders; punding

Year:  2016        PMID: 29213446      PMCID: PMC5642406          DOI: 10.1590/S1980-5764-2016DN1002011

Source DB:  PubMed          Journal:  Dement Neuropsychol        ISSN: 1980-5764


  19 in total

Review 1.  A systematic review of treatments for Impulse Control Disorders and related behaviours in Parkinson's disease.

Authors:  Puja Tanwani; Bruce A Fernie; Ana V Nikčević; Marcantonio M Spada
Journal:  Psychiatry Res       Date:  2014-12-15       Impact factor: 3.222

Review 2.  The prevalence and clinical characteristics of punding in Parkinson's disease.

Authors:  Ashley H Spencer; Hugh Rickards; Alfonso Fasano; Andrea E Cavanna
Journal:  Mov Disord       Date:  2011-03       Impact factor: 10.338

3.  Range of neuropsychiatric disturbances in patients with Parkinson's disease.

Authors:  D Aarsland; J P Larsen; N G Lim; C Janvin; K Karlsen; E Tandberg; J L Cummings
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-10       Impact factor: 10.154

4.  Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson's disease.

Authors:  Claudio Pacchetti; Raffaele Manni; Roberta Zangaglia; Francesca Mancini; Enrico Marchioni; Cristina Tassorelli; Michele Terzaghi; Maria Ossola; Emilia Martignoni; Arrigo Moglia; Giuseppe Nappi
Journal:  Mov Disord       Date:  2005-11       Impact factor: 10.338

Review 5.  Management of impulse control disorders in Parkinson's disease: Controversies and future approaches.

Authors:  Michael Samuel; Maria Rodriguez-Oroz; Angelo Antonini; Jonathan M Brotchie; Kallol Ray Chaudhuri; Richard G Brown; Wendy R Galpern; Melissa J Nirenberg; Michael S Okun; Anthony E Lang
Journal:  Mov Disord       Date:  2015-01-21       Impact factor: 10.338

6.  Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes.

Authors:  S S Rich; J H Friedman; B R Ott
Journal:  J Clin Psychiatry       Date:  1995-12       Impact factor: 4.384

7.  Impulse control disorders and compulsive behaviors associated with dopaminergic therapies in Parkinson disease.

Authors:  Howard D Weiss; Laura Marsh
Journal:  Neurol Clin Pract       Date:  2012-12

8.  Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease.

Authors:  J Michael Bostwick; Kathleen A Hecksel; Susanna R Stevens; James H Bower; J Eric Ahlskog
Journal:  Mayo Clin Proc       Date:  2009-04       Impact factor: 7.616

9.  Psychiatric aspects in Parkinsonism treated with L-dopa.

Authors:  A R Damãsio; J Lobo-Antunes; C Macedo
Journal:  J Neurol Neurosurg Psychiatry       Date:  1971-10       Impact factor: 10.154

10.  Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series.

Authors:  David A Gallagher; Sean S O'Sullivan; Andrew H Evans; Andrew J Lees; Anette Schrag
Journal:  Mov Disord       Date:  2007-09-15       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.